Anticoagulation-free VV ECMO for Acute Respiratory Failure

Recruiting now · Phase 2/Phase 3

Conditions studied: Extracorporeal Membrane Oxygenation Complication

In brief

Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an "anticoagulation-free strategy" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).

Key facts

Study ID

NCT04273607

Run by

Damian Ratano

People needed

40

Starts

2022-09-01

Expected to finish

2027-01-30

Last updated by the study team

2026-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patient with ARDS on VV-ECMO

You may not qualify if…

• Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia, active hemorrhage, any surgery precluding the use of anticoagulation),
• Indication for therapeutic anticoagulation (pulmonary embolism or deep vein thrombosis, chronic anticoagulation therapy before ECMO insertion)
• Low-flow (<2 liters/min) VV-ECMO (ECCO2R)

Where it is running

• Toronto General Hospital — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.